Hans van Houte
2023
In 2023, Hans van Houte earned a total compensation of $1.6M as Chief Financial Officer at Nurix Therapeutics, a 63% decrease compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $193,640 |
|---|---|
| Option Awards | $670,084 |
| Salary | $482,925 |
| Stock Awards | $259,920 |
| Other | $5,418 |
| Total | $1,611,987 |
van Houte received $670.1K in option awards, accounting for 42% of the total pay in 2023.
van Houte also received $193.6K in non-equity incentive plan, $482.9K in salary, $259.9K in stock awards and $5.4K in other compensation.
Rankings
In 2023, Hans van Houte's compensation ranked 730th out of 3,006 executives tracked by ExecPay. In other words, van Houte earned more than 75.7% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 730 out of 3,006 | 76th |
Division Manufacturing | 418 out of 1,650 | 75th |
Major group Chemicals And Allied Products | 283 out of 918 | 69th |
Industry group Drugs | 277 out of 881 | 69th |
Industry Pharmaceutical Preparations | 182 out of 637 | 71st |
Source: SEC filing on March 27, 2024.
van Houte's colleagues
We found two more compensation records of executives who worked with Hans van Houte at Nurix Therapeutics in 2023.